血流储备分数与单纯造影指导血运重建的随机试验荟萃分析
该系统评价与荟萃分析纳入7项随机对照试验共5094例阻塞性冠心病患者,比较血流储备分数(FFR)指导与单纯造影指导血运重建的疗效与安全性。主要终点为主要不良心血管事件(MACE),加权平均随访38个月。结果显示两组长期MACE无差异(13.6% vs 13.9%;RR 0.97,95%CI 0.85–1.11),但FFR指导组置入支架数量更少。
要点
- FFR指导与造影指导血运重建的长期MACE风险无显著差异。
- FFR指导可减少血运重建时的支架置入数量。
- 全因死亡、心血管死亡、再次血运重建、再发心梗及支架血栓均无差异。
核心结论
- 在阻塞性冠心病患者中,FFR指导血运重建未降低长期不良心脏事件风险或各单项结局。
- FFR指导血运重建与支架置入数量更少相关。
研究设计与样本
- 系统评价与荟萃分析,检索MEDLINE、SCOPUS和Cochrane数据库至2021年11月,无语言限制。
- 最终纳入7项随机对照试验,共5094例患者,加权平均随访38个月。
- 采用随机效应模型合并数据,主要终点为MACE。
主要发现
- FFR指导与造影指导的长期MACE发生率分别为13.6%与13.9%(RR 0.97,95%CI 0.85–1.11)。
- FFR指导组支架置入数量更少(标准化均数差=-0.80;95%CI -1.33至-0.27),但总住院费用无差异。
- 全因死亡(RR 1.16,95%CI 0.80–1.68)、心血管死亡(RR 1.27,95%CI 0.50–3.26)、再次血运重建(RR 0.99,95%CI 0.81–1.21)、再发心梗(RR 0.92,95%CI 0.74–1.14)及支架血栓(RR 0.61,95%CI 0.31–1.21)均无差异。
- Meta回归分析未发现急性冠脉综合征(p=0.36)、三支病变比例(p=0.88)或左主干病变(p=0.50)对MACE效应有修饰证据。
临床怎么用
- FFR指导血运重建可作为减少支架置入数量的策略,但未显示长期临床硬终点获益。
- 在急性冠脉综合征、三支病变或左主干病变亚组中,FFR指导的效应未见显著异质性。
局限性
- 纳入试验数量有限(7项),加权平均随访38个月,可能不足以评估极长期结局。
- 原文未报告各试验的具体偏倚风险或异质性定量指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Randomised trials evaluating the efficacy and safety of fractional flow reserve (FFR)-guided versus angiography-guided revascularisation among patients with obstructive coronary artery disease (CAD) have yielded mixed results. AIMS: To examine the comparative efficacy and safety of FFR-guided versus angiography-guided revascularisation among patients with obstructive CAD. METHODS: An electronic search of MEDLINE, SCOPUS and Cochrane databases without language restrictions was performed through November 2021 for randomised controlled trials that evaluated the outcomes of FFR-guided versus angiography-guided revascularisation. The primary outcome was major adverse cardiac events (MACE). Data were pooled using a random-effects model. RESULTS: The final analysis included seven trials with 5094 patients. The weighted mean follow-up duration was 38 months. Compared with angiography guidance, FFR guidance was associated with fewer number of stents during revascularisation (standardised mean difference=-0.80; 95% CI -1.33 to -0.27), but no difference in total hospital cost. There was no difference between FFR-guided and angiography-guided revascularisation in long-term MACE (13.6% vs 13.9%; risk ratio (RR) 0.97, 95% CI 0.85 to 1.11). Meta-regression analyses did not reveal any evidence of effect modification for MACE with acute coronary syndrome (p=0.36), proportion of three-vessel disease (p=0.88) or left main disease (p=0.50). There were no differences between FFR-guided and angiography-guided revascularisation in the outcomes all-cause mortality (RR 1.16, 95% CI 0.80 to 1.68), cardiovascular mortality (RR 1.27, 95% CI 0.50 to 3.26), repeat revascularisation (RR 0.99, 95% CI 0.81 to 1.21), recurrent myocardial infarction (RR 0.92, 95% CI 0.74 to 1.14) or stent thrombosis (RR 0.61, 95% CI 0.31 to 1.21). CONCLUSION: Among patients with obstructive CAD, FFR-guided revascularisation did not reduce the risk of long-term adverse cardiac events or the individual outcomes. However, FFR-guided revascularisation was associated with fewer number of stents. PROSPERO REGISTRATION NUMBER: CRD42021291596.
引用
- Elbadawi, Sedhom, Dang, et al. Fractional flow reserve versus angiography alone in guiding myocardial revascularisation: a systematic review and meta-analysis of randomised trials. Heart. 2022. PMID: 35568392. doi:10.1136/heartjnl-2021-320768
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。